: iStockAnalyst.com Symbols Feed

Sanofi-Aventis to Create China Vitamin JV with Minsheng

Mon, 26 Oct 2009 16:40:37 GMT

Sanofi-Aventis (NYSE: SNY) signed a letter of intent last Saturday to establish a joint venture with Minsheng Pharmaceutical Group of Hangzhou. The JV will focus on OTC vitamin and mineral products. Minsheng already produces the best selling product in the sector: 21-Super Vita multivitamin-multimineral tablets. For Sanofi-Aventis, the JV will provide an entry into China’s OTC market. Sanofi-Aventis will have the majority share in the JV.[More...]

Healthcare M&A Activitiy: Three Healthcare Small Caps Primed For Takeovers

Thu, 22 Oct 2009 16:22:43 GMT

With the healthcare debate still raging in Washington, this should shock you… Healthcare mergers and acquisition (M&A) activity is at an all-time high.[More...]

Celldex Therapeutics (NASDAQ: CLDX): Plenty of Cash and Pending Clinical Catalysts

Tue, 20 Oct 2009 02:19:35 GMT

At the beginning of the month, Celldex Therapeutics (NASDAQ: CLDX) announced the successful completion of its acquisition of CuraGen (formerly CRGN), which strengthens the balance sheet (approx. $85 million in cash / equivalents) while expanding the pipeline and increasing the expected news flow of clinical data catalysts for the combined entity[More...]

The Next Big Thing In Health Care: How To Profit From Immunotherapy & Regenerative Medicine

Wed, 07 Oct 2009 19:22:50 GMT

The procedure has been called "one of the most barbaric mistakes ever perpetrated by mainstream medicine." Back when medicine was highly primitive, the process involved shoving an ice pick-like instrument between the upper eyelid and the eye in hopes of severing certain nerves of the frontal lobe.[More...]

Our Outlook for Health-Care Stocks

Thu, 01 Oct 2009 22:55:00 GMT

The key development on the health-care reform front occurred just before the end of the third quarter. The long-anticipated proposal from the Senate Finance Committee finally materialized and, as is typical of any proposal that attempts to take a centrist approach, was greeted with a barrage of criticism from both ends of the political spectrum.[More...]

Bristol-Myers Squibb (BMY): Riding High

Wed, 30 Sep 2009 16:10:00 GMT

Bristol-Myers Squibb (BMY) stock is trading near the high end of 52 week range. The current P/E of 13.35 is low which suggests the stock could return to a P/E multiple of 15 in the near future. The upside in the stock price would be driven by several factors.[More...]

10 Health-Care Stocks To Consider Buying Now

Mon, 28 Sep 2009 13:38:54 GMT

Our Ultimate Stock-Pickers continue to load up on health-care stocks.[More...]

Which Pharma Pipelines Rank Best?

Thu, 17 Sep 2009 13:42:30 GMT

For the majority of pharmaceutical companies, strong pipelines should offset the approaching patent cliff.[More...]

Attractive Stocks Under $35 - S&P 500 Including Bristol-Myers Squibb (BMY), Harris Corp (HRS)

Thu, 03 Sep 2009 15:41:03 GMT

Fidelity has a fund called the Low Priced Stock fund that only contains stocks with a price of below $35 a share which has been successful in the past. Following a similar strategy ValueExpectations.com has published 2 articles containing attractive stocks[More...]

Post Market Summary: Wall Street Ends Lower On Recovery Fears, E-Trade (NASDAQ: ETFC) Rallies

Mon, 31 Aug 2009 21:46:00 GMT

US stocks finished lower on Monday after a sharp slide in Chinese stocks reignited fears over the pace of the global recovery.[More...]

Earnings Preview: Bristol-Myers 3Q earnings report

Wed, 21 Oct 2009 15:48:00 GMT

NEW YORK - Bristol-Myers Squibb Co., the world's No.
The following is a summary of key developments and analyst opinion related to the period.
OVERVIEW: Growing competition for its top drugs threatens revenue for the maker of blood thinner Plavix, the world's second-bestselling medication, and psychiatric drug Abilify.

: iStockAnalyst.com Symbols Feed

Sanofi-Aventis to Create China Vitamin JV with Minsheng

Healthcare M&A Activitiy: Three Healthcare Small Caps Primed For Takeovers

Celldex Therapeutics (NASDAQ: CLDX): Plenty of Cash and Pending Clinical Catalysts

The Next Big Thing In Health Care: How To Profit From Immunotherapy & Regenerative Medicine

Our Outlook for Health-Care Stocks

Bristol-Myers Squibb (BMY): Riding High

10 Health-Care Stocks To Consider Buying Now

Which Pharma Pipelines Rank Best?

Attractive Stocks Under $35 - S&P 500 Including Bristol-Myers Squibb (BMY), Harris Corp (HRS)

Post Market Summary: Wall Street Ends Lower On Recovery Fears, E-Trade (NASDAQ: ETFC) Rallies

Earnings Preview: Bristol-Myers 3Q earnings report

Chicago Tribune Gail MarksJarvis Column: Recession's End Doesn't Make Stock Picking Easy

Daily Mail, London, Market Report Column

Evening Standard, London, Market Report Column

UPI NewsTrack Business

Onglyza approved for Type 2 Diabetes

Astra 2Q profit up 6 pct as it cuts costs

Home Sales, Earnings Reports Ignite Markets

Dow tops 9,000 as home sales rise for 3rd month

Strong sales boost Bristol-Myers 2Q profit

Bristol-Myers Squibb Achieves Strong Sales, Earnings Performance in Third Quarter

Mead Johnson Reports Solid Third Quarter Results; Narrows Full-Year 2009 Guidance to Top End of Range

Bristol-Myers Squibb Announces Dividend

Bristol-Myers Squibb Completes Acquisition of Medarex, Inc.

Bristol-Myers Squibb Completes Initial Tender Offer for Medarex, Inc. With 87.7% of Shares Tendered; Announces Subsequent Offering Period

Bristol-Myers Squibb Extends Tender Offer for Medarex, Inc.

Morning Watch for Wednesday: Sunwin International Neutraceuticals - August 19, 2009

StockPreacher.com issues Trading Outlook for Spectrum Pharmaceuticals Inc.

AMRI Announces Second Quarter 2009 Results

ZymoGenetics Reports Second Quarter 2009 Financial Results

Form 4 MCBRIDE ANTHONY A For: Nov 01 (10K)

Form 4 Williams R Sanders For: Sep 30 (10K)

Form 4 WEST TOGO D JR For: Sep 30 (10K)

Form 4 GROBSTEIN MICHAEL For: Sep 30 (10K)

Form 4 HOOPER ANTHONY C For: Sep 21 (10K)

Form 4 SIGAL ELLIOT For: Sep 21 (10K)

Form 4 ANDREOTTI LAMBERTO For: Sep 21 (10K)

Form 4 Zito Robert T For: Aug 02 (10K)

Form 4 WEST TOGO D JR For: Jun 30 (10K)

Form 4 GROBSTEIN MICHAEL For: Jun 30 (10K)